Evidence map›Paper›PMID 39994474›Full record

ArticleCommunications chemistry2025

Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction.

Edvin Purić, Mujtaba Hassan, Fredrik Sjövall, Tihomir Tomašič, Mojca Pevec, Jurij Lah, Jaume Adrover Forteza, Anders Sundin, Hakon Leffler, Ulf J Nilsson and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Hidden Interactions: Quantum Perspectives in Drug Design.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Computational Pipeline for Accelerating the Design of Glycomimetics.Journal of chemical information and modeling · 2025
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Edvin PurićDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0003-0836-0548
Mujtaba HassanDepartment of Chemistry, Lund University, Lund, Sweden.
Fredrik SjövallDepartment of Chemistry, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0000-1602-0549
Tihomir TomašičDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0001-5534-209X
Mojca PevecDepartment for Physical Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0001-5968-3895
Jurij LahDepartment for Physical Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0003-1021-3803
Jaume Adrover FortezaDepartment of Chemistry, Biochemistry and Structural Biology, Centre for Molecular Protein Science, Lund University, Lund, Sweden.
Anders SundinDepartment of Chemistry, Lund University, Lund, Sweden.
Hakon LefflerDepartment of Laboratory Medicine, Section MIG, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-4482-8945
Ulf J NilssonDepartment of Chemistry, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-5815-9522
Derek T LoganDepartment of Chemistry, Biochemistry and Structural Biology, Centre for Molecular Protein Science, Lund University, Lund, Sweden. derek.logan@biochemistry.lu.se.ORCID http://orcid.org/0000-0002-0098-8560
Marko AnderluhDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia. marko.anderluh@ffa.uni-lj.si.ORCID http://orcid.org/0000-0003-1768-8246

Funding

EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj) OP20.05187 RI-SI-EATRISEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 765581European Cooperation in Science and Technology (COST) CA18103European Cooperation in Science and Technology (COST) CA18132The Slovenian Research and Innovation Agency (ARIS) P1-0208
6 · The paper itself

Abstract

Galectin-8 is a tandem-repeat galectin consisting of two distinct carbohydrate recognition domains and is a potential drug target. We have developed a library of galectin-8N inhibitors that exhibit high nanomolar K

Identifiers

PMID39994474
PMCPMC11850616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.